Glenmark Receives US FDA Inspection Report for Goa Facility

Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration for its formulations manufacturing facility in Goa. The inspection, conducted from June 22 to June 30, has been closed with a Voluntary Action Indicated (VAI) classification. According to the US FDA framework, VAI means that while objectionable conditions were identified, the regulator does not recommend formal regulatory action and expects the company to undertake voluntary corrective measures. Glenmark disclosed the development through a regulatory filing on Wednesday. The company has 11 manufacturing facilities across four continents and six research and development centres, with a commercial presence in more than 80 countries. The company did not disclose specific observations from the inspection in its exchange filing. The latest regulatory update relates specifically to the Goa formulations facility and follows the completion of the US FDA inspection process. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security